-
1
-
-
0030855116
-
Pathologic prognostic factors for patients with breast carcinoma. Which factors are important?
-
Weidner N, Cady B, Goodson WH 3rd. Pathologic prognostic factors for patients with breast carcinoma. Which factors are important? Surg Oncol Clin North Am. 1997;6:415-462.
-
(1997)
Surg. Oncol. Clin. North Am.
, vol.6
, pp. 415-462
-
-
Weidner, N.1
Cady, B.2
Goodson III, W.H.3
-
2
-
-
0028955244
-
Prognostic factors in breast carcinoma
-
Weidner N. Prognostic factors in breast carcinoma. Curr Opin Obstet Gynecol. 1995;7:4-9.
-
(1995)
Curr. Opin. Obstet. Gynecol.
, vol.7
, pp. 4-9
-
-
Weidner, N.1
-
3
-
-
0041346051
-
Exploiting the hallmarks of cancer: The future conquest of breast cancer
-
Sledge GW Jr, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer. 2003;39:1668-1675.
-
(2003)
Eur. J. Cancer
, vol.39
, pp. 1668-1675
-
-
Sledge Jr., G.W.1
Miller, K.D.2
-
4
-
-
0028227085
-
Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
-
Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol. 1994;12:454-466.
-
(1994)
J. Clin. Oncol.
, vol.12
, pp. 454-466
-
-
Gasparini, G.1
Weidner, N.2
Bevilacqua, P.3
-
5
-
-
0028269324
-
A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma
-
Gasparini G, Boracchi P, Bevilacqua P, et al. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res Treat. 1994;29:59-71.
-
(1994)
Breast Cancer Res. Treat.
, vol.29
, pp. 59-71
-
-
Gasparini, G.1
Boracchi, P.2
Bevilacqua, P.3
-
6
-
-
0027494093
-
Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade
-
Weidner N, Moore DH 2nd, et al. Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade. Am J Surg Pathol. 1993;17:987-994.
-
(1993)
Am. J. Surg. Pathol.
, vol.17
, pp. 987-994
-
-
Weidner, N.1
Moore II, D.H.2
-
7
-
-
0028359509
-
Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody
-
Weidner N, Moore DH 2nd, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol. 1994;25:337-342.
-
(1994)
Hum. Pathol.
, vol.25
, pp. 337-342
-
-
Weidner, N.1
Moore II, D.H.2
Vartanian, R.3
-
8
-
-
0036080841
-
New paradigm for vessel intravasation by tumor cells
-
Weidner N. New paradigm for vessel intravasation by tumor cells. Am J Pathol. 2002;160:1937-1939.
-
(2002)
Am. J. Pathol.
, vol.160
, pp. 1937-1939
-
-
Weidner, N.1
-
9
-
-
0037370476
-
The genetics and genomics of cancer
-
Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet. 2003;33(suppl):238-244.
-
(2003)
Nat. Genet.
, vol.33
, Issue.SUPPL.
, pp. 238-244
-
-
Balmain, A.1
Gray, J.2
Ponder, B.3
-
10
-
-
0035489608
-
Proteomics of breast cancer for marker discovery and signal pathway profiling
-
Hondermarck H, Vercoutter-Edouart AS, Revillion F, et al. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics. 2001;1:1216-1232.
-
(2001)
Proteomics
, vol.1
, pp. 1216-1232
-
-
Hondermarck, H.1
Vercoutter-Edouart, A.S.2
Revillion, F.3
-
11
-
-
25144449912
-
Breast cancer markers
-
Program and abstracts of the Annual Meeting of the American Society of Clinical Pathology; September 18-21, New Orleans, Louisiana
-
Weidner N. Breast cancer markers. Program and abstracts of the Annual Meeting of the American Society of Clinical Pathology; September 18-21, 2003; New Orleans, Louisiana.
-
(2003)
-
-
Weidner, N.1
-
12
-
-
0025618818
-
HER-2/neu oncogene amplification and expression in breast and ovarian cancers
-
Press MF, Jones LA, Godolphin W, Edwards CL, Slamon DJ. HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res. 1990;354A:209-221.
-
(1990)
Prog. Clin. Biol. Res.
, vol.354 A
, pp. 209-221
-
-
Press, M.F.1
Jones, L.A.2
Godolphin, W.3
Edwards, C.L.4
Slamon, D.J.5
-
13
-
-
0027979311
-
Elevated ErbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer
-
Isola JJ, Holli K, Oksa H, et al. Elevated ErbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer. 1994;73:652-658.
-
(1994)
Cancer
, vol.73
, pp. 652-658
-
-
Isola, J.J.1
Holli, K.2
Oksa, H.3
-
14
-
-
0031034106
-
HER-2/neu signal transduction in human breast and ovarian cancer
-
Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 1997;15:1-8.
-
(1997)
Stem. Cells
, vol.15
, pp. 1-8
-
-
Reese, D.M.1
Slamon, D.J.2
-
15
-
-
0042208398
-
The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy
-
Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307-325.
-
(2003)
Oncologist
, vol.8
, pp. 307-325
-
-
Ross, J.S.1
Fletcher, J.A.2
Linette, G.P.3
-
16
-
-
0034666345
-
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer
-
Thor AD, Liu S, Edgerton S, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol. 2000;18:3230-3239.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 3230-3239
-
-
Thor, A.D.1
Liu, S.2
Edgerton, S.3
-
17
-
-
0032445260
-
HER-2/neu as a predictive marker of response to breast cancer therapy
-
Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 1998;52:65-77.
-
(1998)
Breast Cancer Res. Treat.
, vol.52
, pp. 65-77
-
-
Pegram, M.D.1
Pauletti, G.2
Slamon, D.J.3
-
18
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med. 2001;344:783-792.
-
(2001)
N. Engl. J. Med.
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
19
-
-
0035873815
-
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
-
Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587-2595.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 2587-2595
-
-
Seidman, A.D.1
Fornier, M.N.2
Esteva, F.J.3
-
20
-
-
0035868668
-
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
-
for the American Society of Clinical Oncology Tumor Markers Expert Panel
-
Bast RC Jr, Ravdin P, Hayes DF, et al, for the American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 1865-1878
-
-
Bast Jr., R.C.1
Ravdin, P.2
Hayes, D.F.3
-
21
-
-
0028232729
-
Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
-
Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.
-
(1994)
Cancer Res.
, vol.54
, pp. 2771-2777
-
-
Press, M.F.1
Hung, G.2
Godolphin, W.3
Slamon, D.J.4
-
22
-
-
0037099732
-
Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens
-
Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-3105.
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 3095-3105
-
-
Press, M.F.1
Slamon, D.J.2
Flom, K.J.3
-
23
-
-
0035189256
-
Current status of HER2 testing: Caught between a rock and a hard place
-
Schnitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol. 2001;116:806-810.
-
(2001)
Am. J. Clin. Pathol.
, vol.116
, pp. 806-810
-
-
Schnitt, S.J.1
Jacobs, T.W.2
-
24
-
-
0037707280
-
HER2/neu expression in cancer: The pathologist as diagnostician or prophet?
-
Foster CS, Gosden CM, Ke Y. HER2/neu expression in cancer: the pathologist as diagnostician or prophet? Hum Pathol. 2003;34:635-638.
-
(2003)
Hum. Pathol.
, vol.34
, pp. 635-638
-
-
Foster, C.S.1
Gosden, C.M.2
Ke, Y.3
-
25
-
-
0344453811
-
The clinical evaluation of HER-2 status: Which test to use?
-
Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol. 2003;199:411-417.
-
(2003)
J. Pathol.
, vol.199
, pp. 411-417
-
-
Bartlett, J.1
Mallon, E.2
Cooke, T.3
-
26
-
-
0029884715
-
Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
-
Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
-
(1996)
Oncogene
, vol.13
, pp. 63-72
-
-
Pauletti, G.1
Godolphin, W.2
Press, M.F.3
Slamon, D.J.4
-
27
-
-
0034327895
-
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
-
Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 3651-3664
-
-
Pauletti, G.1
Dandekar, S.2
Rong, H.3
-
28
-
-
0037325177
-
Current perspectives on HER2 testing: A review of national testing guidelines
-
Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173-182.
-
(2003)
Mod. Pathol.
, vol.16
, pp. 173-182
-
-
Bilous, M.1
Dowsett, M.2
Hanna, W.3
-
29
-
-
0033694650
-
Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples
-
Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157:1467-1472.
-
(2000)
Am. J. Pathol.
, vol.157
, pp. 1467-1472
-
-
Tanner, M.1
Gancberg, D.2
Di Leo, A.3
-
30
-
-
0036677314
-
Chromogenic in situ hybridization: A novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma
-
Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002;82:1007-1014.
-
(2002)
Lab. Invest.
, vol.82
, pp. 1007-1014
-
-
Dandachi, N.1
Dietze, O.2
Hauser-Kronberger, C.3
-
31
-
-
0038792812
-
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
-
Arnould L, Denoux Y, MacGrogan G, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer. 2003;88:1587-1591.
-
(2003)
Br. J. Cancer
, vol.88
, pp. 1587-1591
-
-
Arnould, L.1
Denoux, Y.2
MacGrogan, G.3
-
32
-
-
0037362714
-
Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer
-
Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol. 2003;119:381-387.
-
(2003)
Am. J. Clin. Pathol.
, vol.119
, pp. 381-387
-
-
Gupta, D.1
Middleton, L.P.2
Whitaker, M.J.3
Abrams, J.4
-
33
-
-
0037333625
-
Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy
-
Park K, Kim J, Lim S, Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003;39:631-634.
-
(2003)
Eur. J. Cancer
, vol.39
, pp. 631-634
-
-
Park, K.1
Kim, J.2
Lim, S.3
Han, S.4
-
34
-
-
0037341394
-
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study
-
Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003;9:923-930.
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 923-930
-
-
Joensuu, H.1
Isola, J.2
Lundin, M.3
|